MannKind

Hapoalim Securities is reiterating its Sell rating on shares of MannKind Corp. (NASDAQ: MNKD). “MannKind announced that due to a potential government shutdown, the FDA has decided to cancel an Afrezza End-of-Review meeting scheduled for April 15,” Hapoalim writes. “We note that other FDA...

Hapoalim is out with its report on Mannkind (NASDAQ: MNKD), reiterating Sell. In a note to clients, Hapoalim writes, "MannKind announced that it will wait for FDA input before beginning the AFFINITY trials. If we assume that MannKind meets with the FDA in April 2011, gets back official feedback in...